Aspira Pathlab promoter Jay Arvind Bhanushali buys 1,424 shares

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Promoter Jay Arvind Bhanushali acquired 1,424 equity shares in open market
  • Stake increases from 7.27% to 7.28% of total share capital
  • Transaction period spanned September 17 to September 24, 2026
  • Disclosure made under SEBI SAST Regulations 2011, Regulation 29(2)
powered bylight_fuzz_icon
52117559

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab & Diagnostics Ltd promoter Jay Arvind Bhanushali acquired 1,424 equity shares in the open market, increasing his holding to 7.28% of the company's total share capital.

The acquisition was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The transaction took place between September 17, 2026, and September 24, 2026. Prior to this purchase, Bhanushali held 7,47,838 shares, representing a 7.27% stake.

Transaction details

The promoter group member executed the purchase through open market transactions. The total diluted share capital of the company remains unchanged at ₹10.29 crore, divided into 1,02,93,000 equity shares of ₹10 each.

Metric Before Acquisition After Acquisition
Number of Shares 7,47,838 7,49,262
Percentage Holding 7.27% 7.28%
Encumbered Shares 0 0

The disclosure confirms that no voting rights were acquired otherwise than by shares, and no warrants or convertible securities were involved in this specific transaction. The acquirer holds no encumbrances such as pledges or liens on these shares.

Regulatory compliance

This filing serves as a mandatory disclosure for substantial acquisitions where the change in holding is less than 5% but triggers reporting requirements for promoters. The company's registered office is located in Ghatkopar (West), Mumbai. The disclosure was submitted to BSE Limited, where the scrip is listed.

Historical Stock Returns for Aspira Pathlab

1 Day5 Days1 Month6 Months1 Year5 Years
-0.02%+13.04%+50.29%+124.14%+110.12%0.0%

Will the promoter's incremental buying signal a broader accumulation trend or precede a larger stake-building campaign?

How might this minor increase in promoter holding influence retail investor sentiment and trading volume for Aspira Pathlab shares?

Are there any upcoming corporate actions or strategic announcements expected that could justify the promoter's continued market participation?

Aspira Pathlab net profit falls to ₹5.13 lakh in FY26

scanx
Reviewed by
Riya DScanX News Team
Key Highlights
  • Net profit declined to ₹5.13 lakh in FY26 from ₹207.26 lakh in FY25
  • 53rd AGM held virtually on September 25, 2026, with 28 attendees
  • Shareholders approved re-designation of Nikunj Velji Mange as Managing Director
  • Material related party transaction with Yashraj Research Foundation approved
powered bylight_fuzz_icon
51893838

*this image is generated using AI for illustrative purposes only.

Aspira Pathlab & Diagnostics Limited reported a net profit of ₹5.13 lakh for the financial year ended March 31, 2026, marking a significant decline from the previous year's performance.

The disclosure was made during the 53rd Annual General Meeting (AGM) held on September 25, 2026, via Video Conferencing (VC) and Other Audio Visual Means (OAVM). Chairman Dr. Haseeb Ahmad Drabu informed shareholders that the current year's profit stood in stark contrast to the net profit of ₹207.26 lakh recorded in the preceding fiscal year.

Meeting proceedings and attendance

The AGM commenced at 2:10 pm and concluded at 2:30 pm. The meeting was chaired by Dr. Haseeb Ahmad Drabu, with Managing Director Nikunj Velji Mange and Director Vaibhav Odhekar in attendance. Mrs. Kiran Raghavendra Awasthi, Chairperson of the Audit and Nomination & Remuneration Committees, was also present.

Attendance details for the virtual meeting are as follows:

Category Promoter & Promoter Group Public Total
In Person Not Applicable Not Applicable -
Through Proxy/Authorised Representative Not Applicable Not Applicable -
Video Conferencing and OAVM 1 27 28

Mr. Manoj Jain, Partner of M/s. Sarda Soni Associates LLP, attended as the representative of the Statutory Auditors. Ms. Prajakta V. Padhye, Partner of M/s. Nilesh A. Pradhan & Co., LLP, served as the Scrutinizer and Secretarial Auditor.

Key resolutions passed

Shareholders voted on several ordinary and special business items using remote e-voting facilities provided by NSDL. The voting window opened on September 22, 2026, and closed on September 24, 2026.

The following resolutions were transacted:

  1. Adoption of audited standalone financial statements for FY26.
  2. Re-appointment of Nikunj V Mange as Director retiring by rotation.
  3. Approval of material related party transaction with M/s. Yashraj Research Foundation.
  4. Re-designation of Nikunj Velji Mange as Managing Director.
  5. Regularization of Vaibhav Odhekar’s appointment as Executive Director.

What the numbers show

The financial data presented at the AGM highlights a dramatic contraction in profitability. Net profit fell to ₹5.13 lakh in FY26 from ₹207.26 lakh in FY25. This represents a decline of over 97%, indicating severe pressure on the bottom line despite the continuation of operations. The magnitude of this drop suggests either a significant increase in operational costs, a sharp reduction in revenue, or one-time exceptional charges that impacted the FY26 results, although specific drivers were not detailed in the meeting minutes.

Historical Stock Returns for Aspira Pathlab

1 Day5 Days1 Month6 Months1 Year5 Years
-0.02%+13.04%+50.29%+124.14%+110.12%0.0%

What specific operational or revenue factors drove the 97% collapse in net profit for Aspira Pathlab in FY26?

How will the approval of material related party transactions with Yashraj Research Foundation impact Aspira's future cost structure and governance transparency?

Does the re-designation of Nikunj Velji Mange as Managing Director signal a strategic pivot to address the severe profitability decline?

More News on Aspira Pathlab

1 Year Returns:+110.12%